GlassScriptPhysician profile
Lloyd D Weddington
NPI 1043288418
$6,879.54
in general payments reported to CMS, 2019-2025
49 companies · $1,344 in 2025
The $1,344 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,544 · 2020: $523 · 2021: $435 · 2022: $542 · 2023: $988 · 2024: $1,504 · 2025: $1,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,835.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $918.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $752.82 | 2019-2025 | Vraylar, Synthroid |
| Amgen INC. | $688.01 | 2019-2024 | Otezla, Repatha, Prolia |
| Pfizer INC. | $466.52 | 2019-2025 | |
| Lilly USA, LLC | $439.20 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $315.20 | 2019-2025 | |
| Exact Sciences Corporation | $311.46 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $279.63 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $270.75 | 2019-2024 | Farxiga |
| Dexcom, INC. | $188.92 | 2022-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $188.70 | 2019-2025 | Veozah |
| Abbott Laboratories | $158.34 | 2020-2025 | Freestyle Libre 3 |
| Shield Therapeutics INC | $155.84 | 2023-2025 | Accrufer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.49 | 2019-2025 | Xifaxan |
| Allergan, INC. | $145.12 | 2019-2020 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lloyd Weddington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.